Lineage Cell Therapeutics (LCTX) Treasury Shares (2010 - 2026)

Lineage Cell Therapeutics' Treasury Shares history runs 6 years deep, the most recent figure standing at $2.9 million for Q4 2016.

• On a quarterly basis, Treasury Shares fell 83.97% year-over-year to $2.9 million in Q4 2016; TTM through Dec 2016 was $2.9 million, a 83.97% decrease from a year earlier, with the FY2016 full-year figure at $2.9 million, down 83.97% from the prior year.
• Treasury Shares was little changed at $2.9 million in Q4 2016 per LCTX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Treasury Shares topped out at $939000.0 in Q4 2022 and bottomed at $248000.0 in Q1 2026.
• The 5-year median for Treasury Shares is $501000.0 (2024), against an average of $494583.3.
• Across the five-year window, Treasury Shares soared 413.81% in 2013 and plunged 85.47% in 2016, its largest moves.
• Year by year, Treasury Shares stood at $8.4 million in 2012, then surged by 413.81% to $43.0 million in 2013, then tumbled by 53.78% to $19.9 million in 2014, then declined by 9.34% to $18.0 million in 2015, then tumbled by 83.97% to $2.9 million in 2016.
• Per Business Quant, the three latest LCTX Treasury Shares figures stand at $2.9 million (Q4 2016), $2.9 million (Q3 2016), and $2.9 million (Q2 2016).